Advertisement

Perihilar and Distal Extrahepatic Bile Duct Carcinoma

  • Paul J. KellyEmail author
Chapter
  • 16 Downloads

Abstract

Perihilar and Distal Extrahepatic Bile Duct Carcinoma: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make the corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular invasion, lymph node involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and TNM8 are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response. A summary is given of the more common non-carcinoma malignancies that are encountered at this site in diagnostic practice.

Keywords

Perihilar bile duct Extrahepatic bile duct Sclerosing cholangitis Klatskin tumour Cholangiocarcinoma TNM8 

Bibliography

  1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.CrossRefGoogle Scholar
  2. Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017;11:13–26.CrossRefGoogle Scholar
  3. Bosman FT, Carneiro F. GI WHO classification of tumours. Digestive system tumours. 5th ed.; 2019.Google Scholar
  4. Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2.Google Scholar
  5. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–79.Google Scholar
  6. The Royal College of Pathologists. Cancer Datasets (Oesophageal Carcinoma, Gastric Carcinoma, Carcinomas of the Pancreas, ampulla of Vater and Common Bile Duct, Colorectal Cancer, Gastrointestinal Stromal Tumours (GISTs), Liver Resection Specimens and Liver Biopsies for Primary and Metastatic Carcinoma, Endocrine Tumours of the Gastrointestinal Tract including Pancreas) and Tissue Pathways (Gastrointestinal and Pancreatobiliary Pathology, Liver Biopsies for the Investigation of Medical Disease and for Focal Liver Lesions). https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html
  7. Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Ann Hepatol. 2017;16:133–9.CrossRefGoogle Scholar
  8. Wyatt JW. Cholangiocarcinoma – new concepts and classifications. Diagn Histopathol. 2011;17:539–47.CrossRefGoogle Scholar
  9. Zhang W, Yan LN. Perihilar cholangiocarcinoma: Current therapy. World J Gastrointest Pathophysiol. 2014;5:344–54.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Institute of Pathology, Royal Victoria HospitalBelfastUK

Personalised recommendations